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Abstract
Background: Interleukin-1 (IL-1) is a cytokine involved in the initiation and amplification of the
defence response in infectious and inflammatory diseases. IL-1 receptor antagonist (IL-1ra) is an
inactive member of the IL-1 family and represents one of the most potent mechanisms for
controlling IL-1-dependent inflammation. IL-1ra has proven effective in the therapy of acute and
chronic inflammatory diseases in experimental animal models and also in preliminary clinical trials.
However, optimisation of therapeutic schedules is still needed. For instance, the use of drug
delivery systems targeting specific mucosal sites may be useful to improve topical bioavailability and
avoid side effects associated with systemic administration.
Results:  In order to develop systems for the delivery of IL-1ra to mucosal target sites, a
Streptococcus gordonii strain secreting human IL-1ra was constructed. The recombinant IL-1ra
produced by S. gordonii was composed of the four amino acid residues RVFP of the fusion partner
at the N-terminus, followed by the mature human IL-1ra protein. RFVP/IL-1ra displayed full
biological activity in vitro in assays of inhibition of IL-1β-induced lymphocyte proliferation and was
released by recombinant S. gordonii in vivo both at the vaginal and the gastrointestinal mucosa of
mice. RFVP/IL-1ra appeared beneficial in the model of ulcerative colitis represented by IL-2-/- mice
(knock-out for the interleukin-2 gene), as shown by the body weight increase of IL-2-/- mice locally
treated with S. gordonii producing RFVP/IL-1ra.
Conclusions: These results indicate that recombinant S. gordonii can be successfully used as a
delivery system for the selective targeting of mucosal surfaces with therapeutic proteins.
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Background
In several inflammatory disorders, local delivery of thera-
peutic molecules is often preferred to systemic treatments.
Therefore, the design and development of novel drug
delivery systems able to reach specific tissues and organs
is crucial to obtain high selectivity and efficacy with lim-
ited side effects. Drug delivery by gene therapy may repre-
sent a valid strategy for the treatment of immune-based
inflammatory diseases, such as rheumatoid arthritis, mul-
tiple sclerosis, allergic asthma, diabetes, and inflamma-
tory bowel disease (IBD) [1]. Patients suffering from IBD
(e.g., Crohn's disease and ulcerative colitis) are currently
treated with corticosteroid drugs, immunosuppressants,
and antibiotics. Novel therapeutic approaches, including
local inhibition of pro-inflammatory cytokines (e.g., TNF-
α and IL-1β) and prebiotic/probiotic modulation of the
enteric flora, are also under investigation [2–4].
The IL-1 family of cytokines includes two agonist pro-
teins, IL-1α and IL-1β, and one antagonist protein, IL-1ra.
IL-1β (and in certain cases also IL-1α) is a very potent
immunostimulatory and inflammatory cytokine, respon-
sible for initiating and amplifying the host response to
invasion. However, if not properly controlled, IL-1 can
cause fever, acute inflammation, tissue destruction, organ
failure, and eventually shock and death (reviewed in [5]).
IL-1ra is capable of inhibiting IL-1 both in vitro and in vivo,
thus representing a natural powerful mechanism to con-
trol IL-1-dependent responses and avoid pathological
derangements (reviewed in [6–8]). IL-1ra functions as a
competitive receptor antagonist with no detectable ago-
nist activity. In experimental animal models, IL-1ra has
demonstrated excellent therapeutic potential against
acute and chronic inflammatory pathologies [6–9], also
being effective in prolonging survival during endotoxic
shock [8,10–12]. Gene therapy with adenoviral vectors
carrying the IL-1ra gene also yielded promising results in
experimental models of type 1 diabetes and ischemic
brain damage [13,14]. In human clinical trials, IL-1ra has
been administered to patients with septic shock, rheuma-
toid arthritis, graft-versus-host disease, and multiple scle-
rosis (reviewed in [8]). While only a modest benefit was
achieved in patients with septic shock [8,15], IL-1ra
clearly reduced progression of joint destruction due to
rheumatoid arthritis [8,16–18]. In IBD, progression and
chronicisation of the disease appears to be linked to an
imbalance between pro-inflammatory and anti-inflam-
matory cytokines [19,20]. In particular, the mucosal
imbalance between inflammatory IL-1β and anti-inflam-
matory IL-1ra apparently plays a critical role [19,21–23],
and the presence of the allele 2 of the IL-1ra gene is asso-
ciated with increased incidence and severity of the disease
[24–26]. So far, pre-clinical studies have demonstrated
beneficial effects of anti-cytokine approaches, including
IL-1ra, in experimental models of colitis in rats and rab-
bits (reviewed in [8,19]).
Streptococcus gordonii is a human oral commensal that has
been proposed as a delivery vehicle for vaccine antigens
and microbicides [27–30]. Using the M6 protein of Strep-
tococcus pyogenes as a fusion partner, a host-vector system
was developed in S. gordonii allowing either expression at
the cell surface [31], or secretion of heterologous proteins
into the culture medium [32]. Due to its capability of col-
onising certain host mucosae (reviewed in [27]), S. gordo-
nii represents a promising candidate for delivering vaccine
antigens, recombinant antibodies, and therapeutic drugs
to mucosal surfaces.
In the present study, an S. gordonii strain producing and
delivering human IL-1ra to target mucosal sites was con-
structed. The results obtained show that the recombinant
IL-1ra secreted by S. gordonii is biologically active in vitro
and, when administered in vivo in the gastrointestinal
mucosa, alleviated the symptoms of IBD in an experimen-
tal animal model.
Results
Production of human IL-1ra by S. gordonii
By using the streptococcal M6 protein as the fusion part-
ner [31], an S. gordonii strain secreting human IL-1ra into
the culture medium was constructed and denominated
GP1300. The presence of the emm6 signal sequence at the
N-terminus and of two stop codons at the C-terminus of
the fusion allowed translocation and secretion of the pro-
tein, respectively. After cleavage of the M6 leader peptide
(42 amino acids), the recombinant IL-1ra consisted in the
first four amino acid residues of M6 (RVFP) followed by
152 amino acids of the mature human IL-1ra. The result-
ing fusion protein (156 amino acids) was thus denomi-
nated RVFP/IL-1ra (Figure 1A). Production of RVFP/IL-1ra
by GP1300 was assessed by Western blot analysis of
trichloroacetic acid (TCA)-precipitated proteins released
into the culture medium using IL-1ra-specific polyclonal
antibodies. A protein band of approximately 19 kDa (the
expected molecular mass of the fusion protein is 17.2
kDa) was detected in the GP1300 sample, while no reac-
tivity was observed in the control sample (Figure 1B). The
amount of recombinant IL-1ra secreted by S. gordonii was
0.1 mg per litre, as estimated by ELISA. These results indi-
cate that S. gordonii is a suitable system to produce recom-
binant human IL-1ra.
IL-1ra secreted by S. gordonii is biologically active
In order to verify that RVFP/IL-1ra produced by the
GP1300 strain retains IL-1ra-like biological activity, its
ability to inhibit IL-1-mediated proliferation of murine
thymocytes was assessed. As a control, a reference stand-
ard of wild type human IL-1ra expressed in Escherichia coliBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/15
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was used. IL-1β-induced proliferation could be inhibited
in a dose-dependent fashion by both wild type IL-1ra and
the culture medium of S. gordonii GP1300 (Figure 2A).
Specific inhibitory activities of the GP1300 culture
medium (containing 0.1 mg/litre of RVFP/IL-1ra) and of
wild type IL-1ra were 1.25 × 106 Antagonist Units (AU)
per mg and 1.0 × 106 AU/mg, respectively. Culture super-
natant of the control S. gordonii GP204 strain did not con-
tain measurable levels of IL-1 inhibitory activity (data not
shown). In order to verify that the presence of the RVFP
residues did not affect the biological activity of IL-1ra pro-
duced by S. gordonii, RVFP/IL-1ra was also expressed in E.
coli, purified, and assayed for IL-1 inhibitory activity as
described above. Also in this case, the dose-dependent
inhibition of IL-1β-induced thymocyte proliferation by
RVFP/IL-1ra was fully comparable to that of the reference
standard wild type IL-1ra, with a specific inhibitory activ-
ity of approximately 1.25 × 106 AU/mg in both cases (Fig-
ure 2B). These results show that RVFP/IL-1ra is capable of
inhibiting IL-1 to an extent fully comparable to that of
wild type IL-1ra, indicating that the presence of RVFP at
the N-terminal does not affect the biological activity of IL-
1ra produced by S. gordonii.
Structure and production of RVFP/IL-1ra by S. gordonii Figure 1
Structure and production of RVFP/IL-1ra by S. gordonii. A. Structure of RVFP/IL-1ra produced by S. gordonii. By using 
the streptococcal M6 protein as the fusion partner, a recombinant protein composed of the M6 signal peptide (42 amino acids; 
hatched), the first four amino acids of M6 (RVFP; black), and the mature human IL-1ra (152 amino acids; white) was produced. 
After cleavage of the M6 leader peptide, RVFP/IL-1ra (156 amino acids) is secreted into the culture medium. A schematic rep-
resentation of the different parts of the fusion protein is shown in the upper part of the figure. B. Immunoblot analysis of total 
proteins present in the culture supernatant of S. gordonii. Culture supernatants of the control GP204 strain (lane 1) and of the 
RVFP/IL-1ra-producing GP1300 strain (lane 2) were precipitated with TCA, separated by 15% SDS-PAGE, and reacted with a 
polyclonal antibody to human IL-1ra. Positions of molecular mass standards are indicated to the left.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/15
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IL-1ra is produced in vivo by recombinant S. gordonii
One of the potential uses of IL-1ra-producing S. gordonii
is the local delivery of the anti-inflammatory molecule to
a specific mucosal site. Therefore, the ability of S. gordonii
to stably release IL-1ra at the mucosal level was tested. In
order to improve recovery of bacteria from mucosal sites,
a double-antibiotic-resistant strain was constructed by
transforming S. gordonii GP1300 with the chromosomal
DNA of S. gordonii GP204 [33], that carries a point muta-
tion conferring resistance to streptomycin. The new eryth-
romycin- and streptomycin-resistant strain was
denominated GP1294. S. gordonii GP1294 was inocu-
lated intravaginally into mice, and the presence of recom-
binant bacteria was evaluated in vaginal samples collected
from mice once per week. In vivo production of IL-1ra by
S. gordonii was assessed by both immunoblotting on
erythromycin- and streptomycin-resistant bacterial colo-
nies and immunofluorescence directly carried out on vag-
inal smears using anti-IL-1ra specific antibodies. In
accordance with published data [34], it was possible to
isolate recombinant bacteria producing RVFP/IL-1ra from
vaginal samples for eight consecutive weeks (data not
shown). In addition, to verify that S. gordonii was also
capable of releasing IL-1ra in vivo in the gastrointestinal
Inhibition of IL-1-mediated thymocyte proliferation Figure 2
Inhibition of IL-1-mediated thymocyte proliferation. A. Thymocyte proliferation induced by 0.3 ng/ml of IL-1β (β; grey 
bar) could be inhibited in a dose-dependent fashion by a standard preparation of wild type human IL-1ra expressed in E. coli 
(open triangles). The IL-1 inhibitory activity of the wild type IL-1ra reference standard was compared to that of the culture 
supernatant of recombinant S. gordonii GP1300 (solid triangles), which contained 0.1 mg/litre RVFP/IL-1ra (as assessed by 
ELISA). B. Thymocyte proliferation to 0.3 ng/ml IL-1β (β; grey bar) was inhibited in a dose-dependent fashion by both the wild 
type IL-1ra reference standard (open triangles) and the recombinant RVFP/IL-1ra expressed in E. coli (solid squares). Results 
are the mean ± SEM of 3–9 replicate determinations within single experiments, representative of five performed. SEM lower 
than 10 % are not shown. Background thymocyte proliferation in culture medium without IL-1β (m, open bar) is also reported.
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tract (GI), mice were inoculated via the intragastric route
with the GP1294 strain. In this case, IL-1ra production
was tested by ELISA on different parts of the GI tract of
mice sacrificed 3, 11, and 28 days after bacterial adminis-
tration. IL-1ra was detected in GI samples up to day 11
from the last inoculum with the highest amounts of
antagonist found in the stomach and caecum (Table 1). It
was not possible to detect IL-1ra in the GI tract of mice
sacrificed four weeks after inoculum (Table 1). These data
confirm that S. gordonii may represent a reliable system to
deliver a drug molecule, such as IL-1ra, to target mucosal
sites.
IL-1ra-producing S. gordonii has beneficial effects in 
murine IBD
Mice deficient in the interleukin-2 gene (IL-2-/-) spontane-
ously develop a progressive IBD similar to human ulcera-
tive colitis between 4 to 15 weeks of age [35,36]. The
disease is associated with increased levels of IL-1 [37,38],
and treatment with systemic IL-1ra diminishes colitis
severity [37]. As we showed that S. gordonii GP1294 was
able to release IL-1ra in the GI tract of mice (Table 1), it
was thus examined whether production of IL-1ra by S. gor-
donii in the GI tract of IL-2-/- mice could be effective in
decreasing the IBD-like pathology. Starting at 4 weeks of
age, animals were treated for 7 consecutive weeks with
either S. gordonii GP1294 or the GP204 control strain. As
a measure of disease progression, body weight was
recorded up to the 15th week of age. A significant weight
gain was observed in the first week of treatment (week 4
to 5) in the animal group inoculated with the GP1294
strain (Figure 3). A more consistent weight increase was
achieved from week 8 to week 10.5 in mice treated with S.
gordonii GP1294, with statistically significant differences
compared to animals inoculated with the control strain
(Figure 3). After treatment interruption at week 10, differ-
ences in body weight between the two animal groups
could no longer be detected. These results suggest that
recombinant S. gordonii, that is able to release bioactive IL-
1ra in the GI tract, can improve the symptoms of ulcera-
tive colitis. It may be hypothesized that such improve-
ment is due to the inhibition of IL-1-dependent
inflammation by IL-1ra, although further investigation is
needed to confirm this hypothesis.
Discussion
IL-1 is a potent immunostimulating and inflammatory
cytokine playing a major role in the onset and develop-
ment of the defence response. IL-1 activity can be detri-
mental if not properly controlled, resulting in the
development and chronicisation of several immune and
inflammatory pathologies. Inhibition of IL-1 can be
accomplished by several means, including the use of neu-
tralising antibodies, soluble receptors, inhibitors of IL-1-
activating enzymes, and most of all the receptor antago-
nist IL-1ra [5]. IL-1ra has been used in pre-clinical studies
of autoimmune and immune-mediated diseases, septic
shock, localised inflammatory diseases, neurodegenera-
tive conditions, metabolic dysfunctions, and cancer
(reviewed in [8]). Encouraging results were obtained in
both osteoarthritis animal models and rheumatoid arthri-
tis patients either by local/systemic administration of IL-
1ra [8,18,39], or by gene therapy using ex vivo transfer of
IL-1ra-transfected synovial fibroblasts directly into the
joints [8,16–18,40–43]. Delivery of anti-inflammatory
drugs to mucosal surfaces may also be crucial in patients
suffering from localised inflammatory conditions, such as
gingival inflammation, periodontal disease, sinusitis,
allergic rhinitis, vaginal infections, otitis, conjunctivitis,
Sjögren syndrome and IBD. However, gene therapy is
sometimes not feasible for mucosal drug delivery, because
of the intrinsic problems of the approach (that implies
genetic manipulation of human cells and their re-intro-
duction into the body) and of those related to the choice
of the appropriate target cells.
Table 1: IL-1ra in the gastro-intestinal tract of mice inoculated intragastrically with recombinant S. gordonii GP1294.
IL-1ra (OD450) at different time points after bacterial inoculuma
Sample b (day 3) (day 11) (day 28)
Stomach 0.478 0.244 0.000
Small intestine 0.061 0.062 0.000
Caecum 0.051 0.029 0.000
Colon 0.028 0.055 0.000
Caecum content 0.026 0.283 0.000
Faeces 0.036 0.025 0.000
a The presence of IL-1ra was determined by ELISA and expressed as net OD readings at 450 nm. As reference, standard IL-1ra readings were the 
following: 50 pg/ml, 0.018; 100 pg/ml, 0.030; 500 pg/ml, 0.236; 1000 pg/ml, 0.575. b IL-2-/- mice inoculated with the IL-1ra-expressing S. gordonii 
GP1294 strain were sacrificed 3, 11, and 28 days after the last inoculum. Different parts of the GI tract were removed, homogenised, and subjected 
to ELISA. Culture supernatants of strains GP1294 and GP204 were used as positive and negative controls, respectively.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/15
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In this work, a strategy for mucosal drug delivery is pro-
posed, consisting in the in situ synthesis and release of the
recombinant protein IL-1ra by a genetically engineered S.
gordonii strain. Mucosal delivery of therapeutics by recom-
binant bacteria has been successfully attempted for the
first time by Steidler et al. [44,45] and more recently also
by other groups [29,46,47]. However, the use of anti-
inflammatory IL-1ra is novel in the field. S. gordonii has
already been described as a delivery vehicle for vaccine
antigens and microbicides [27–30]. By using the previ-
ously developed host-vector system [31], the coding
sequence of the mature human IL-1ra was cloned in-
frame into the emm6 gene, encoding the M6 protein of S.
pyogenes. After cleavage of the M6 leader peptide, the
resulting mature fusion protein includes the RVFP resi-
dues of the M6 protein and the 152 amino acids of human
IL-1ra. Production of recombinant RVFP/IL-1ra was con-
firmed by Western blotting of proteins secreted into the
culture supernatant. In accordance with previous data
[32], the presence of four amino acids of M6 was sufficient
to ensure a correct translocation and release of the fusion
protein into the medium to a concentration of approxi-
mately 0.1 mg per litre. Although the quantity of recom-
binant human IL-1ra produced by S. gordonii is not as
large as that reported in other studies [48,49], high pro-
ductivity is not a major issue here, since this work aims at
Body weight of IBD-affected IL-2-deficient mice treated with RVFP/IL-1ra producing S. gordonii Figure 3
Body weight of IBD-affected IL-2-deficient mice treated with RVFP/IL-1ra producing S. gordonii. Two groups of 
six IL-2-/- mice were inoculated intragastrically with 1 × 1010 CFU of either S. gordonii strain GP1294 (RVFP/IL-1; solid triangles) 
or GP204 (control; open triangles). One untreated mouse (open circles) served as a control of disease progression. Starting at 
4 weeks of age, bacteria were administered (indicated by arrows) to mice twice per week for a total of 7 consecutive weeks. 
Body weight (in grams) of individual mice was recorded twice per week up to 15 weeks of age, and expressed as mean ± SD. 
Statistically significant (t test) differences between mice treated with S. gordonii GP1294 and those receiving GP204 are repre-
sented by asterisks (*, P < 0.05; **, P < 0.01).
0
10
12
14
16
18
20
22
24
0 3 4 5 6 7 8 9 10 11 12 13 14 15
GP1294
GP204
control
Time (weeks)
GP1294
GP204
control
**
*
*
* *
* **
*
B
o
d
y
 
w
e
i
g
h
t
(
g
)BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/15
Page 7 of 11
(page number not for citation purposes)
developing a mucosal drug delivery system rather than a
system for large-scale production of drugs. Indeed, a con-
tinuous and prolonged (8 weeks) production of IL-1ra
was detected at the level of the vaginal mucosa of mice fol-
lowing topical delivery of a single inoculum of IL-1ra-
secreting  S. gordonii. In addition, S. gordonii was also
shown to release recombinant RVFP/IL-1ra in vivo in the
GI tract of mice for at least 11 days after bacterial admin-
istration. Therefore, this approach appears suitable for
achieving the in vivo release of RVFP/IL-1ra at mucosal
surfaces.
The RVFP/IL-1ra produced by S. gordonii is biologically
active. Both RVFP/IL-1ra-containing S. gordonii superna-
tant and purified RVFP/IL-1ra were able to inhibit IL-1-
induced thymocyte proliferation in a dose-dependent
manner, with an antagonist activity fully comparable to
that of wild type IL-1ra. Thus, addition of four extra
amino acids at the N-terminal of IL-1ra did not alter its IL-
1-inhibitory activity, confirming that S. gordonii is a feasi-
ble system for producing biologically active human pro-
teins. The preliminary evidence of the activity of RVFP/IL-
1ra delivered in vivo by S. gordonii was obtained in the
murine model of IBD in IL-2-/- mice. The IBD pathology
was chosen because a significant alteration of the IL-1β/
IL-1ra homeostatic equilibrium towards inflammation is
present in IBD [21,23]. Few weeks after birth, IL-2-/- mice
spontaneously develop IBD-like symptoms, including
diarrhoea, intestinal bleeding, frequent rectal prolapse,
and also weight loss [35]. In IL-2-/- mice colitis there are
increased levels of IL-1 [37,38], and treatment with IL-1ra
reduces disease onset and progression [37]. By carefully
monitoring body weight fluctuations as an index of IBD
progression, a significant weight gain was observed in ani-
mals inoculated with the RVFP/IL-1ra-producing S. gordo-
nii GP1294 strain as compared to control animals. The
beneficial effects of recombinant bacteria was observed
for the whole period of treatment. The present results thus
suggest that mucosal delivery of anti-inflammatory IL-1ra
produced by recombinant S. gordonii can reduce disease
severity in the IL-2-/- IBD-like pathology, representing the
"proof-of-principle" of the suitability of S. gordonii for
mucosal delivery of therapeutic proteins. This finding is in
agreement with a recent report describing effective reduc-
tion and prevention of ulcerative colitis like symptoms in
two different animal models of IBD by using genetically
engineered Lactococcus lactis producing anti-inflammatory
murine IL-10 [45]. In our case, to prove the actual thera-
peutic effectiveness of IL-1ra produced by S. gordonii, a
more extensive study with a detailed analysis of inflam-
matory parameters in this and other animal models
would be required.
S. gordonii can colonise the oral and vaginal mucosa of
mice for up to eight weeks [27]. Although the bacterium
persists in the murine intestinal mucosa for few weeks
[28], it does not efficiently colonise the murine gut. This
could explain why, differently from the long-lasting colo-
nisation in the vagina, the beneficial effects of intragastri-
cally delivered IL-1ra-producing S. gordonii on IBD
progression were limited to the period of treatment. How-
ever, this fact may still be of great advantage in terms of
future therapeutic applications, as it allows a thorough
control of timing and dosage of drug delivery.
In conclusion, the drug delivery system here described is
suitable for further developments for human use. How-
ever, in this case, additional modifications would be
needed to avoid the escape of a genetically modified
micro-organism into the external environment through
faecal excretion. This containment could be achieved for
instance by making the micro-organism auxotrofic for an
essential molecule not available in the environment, as
recently described by Steidler et al. [50].
Conclusions
The possibility of limiting and controlling the delivery of
a cytokine inhibitor of high and selective activity such as
IL-1ra may offer enormous advantages in terms of efficacy
and safety in the treatment of certain inflammatory disor-
ders, where the pathogenic role of IL-1 is demonstrated. In
the present work, we propose the use of S. gordonii to
deliver IL-1ra in a biologically active form to affected
mucosal surfaces. The system is safe, since S. gordonii is a
commensal micro-organism of the human oral cavity, and
it can be easily controlled in terms of quantity of drug
produced and duration of treatment. Moreover, by using
the recently developed co-expression system [51], it is also
feasible to construct a drug delivery system simultane-
ously producing IL-1ra together with other anti-inflam-
matory cytokines (e.g.  IL-4, IL-10), neutralising
antibodies, or soluble receptors. In conclusion, S. gordonii
could represent a novel, cost-effective therapeutic
approach, in alternative to gene therapy, for the selective
delivery of drugs to diseased mucosal sites.
Methods
S. gordonii strains
Strain GP1221 [31] was the recipient for transformation
experiments and the control in Western blotting and thy-
mocyte proliferation assays. Strain GP204 [33] was used
as a control in animal experiments. S. gordonii GP1300
and GP1294 secrete human IL-1ra into the culture
medium. Strains were grown in Tryptic Soy Broth (TSB;
Difco, Detroit, MI) at 37°C with 5% CO2. Antibiotics
were added at the following concentrations: erythromycin
at 1 µg/ml, kanamycin and streptomycin at 500 µg/ml.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/15
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Construction of S. gordonii strains producing human IL-
1ra
An S. gordonii strain secreting human IL-1ra into the cul-
ture medium was constructed using the previously
described host-vector system [31]. The cDNA encoding
the mature human IL-1ra (accession no. M63099) was
PCR-amplified using primers IL-1ra-Forward (5'-
GGCTCTAGACCATCTGGTCGTAAGTCT-3', the XbaI
restriction site is underlined) and IL-1ra-Reverse (5'-CAT-
GAATTCCATGGTACCAGCTGCAGA-3', the EcoRI site is
underlined), and cloned in-frame into the emm6 gene of
plasmid pSMB55 [31] digested with AvrII and EcoRI. The
new plasmid was named pSMB55/IL-1ra. In order to
achieve protein translocation across the cell wall, the
sequence encoding the first four amino acids (RVFP) of
the M6 protein was added at the 5'-end of the IL-1ra cod-
ing sequence, whereas the presence of two transcriptional
stop codons at the 3'-end of IL-1ra allowed secretion of
the protein. As recombinant IL-1ra produced by S. gordonii
is preceded by the RVFP residues, it will be referred to as
RVFP/IL-1ra. Competent cells of S. gordonii GP1221 were
transformed with plasmid pSMB55/IL-1ra to obtain the
erythromycin-resistant strain GP1300. In order to con-
struct an erythromycin- and streptomycin-resistant strain
for animal experiments, GP1300 was transformed with
the chromosomal DNA of S. gordonii GP204 [33], and the
new strain was denominated GP1294. Procedures for S.
gordonii transformation, screening and genetic analysis of
transformants were as previously described [33].
Determination of IL-1ra production by recombinant S. 
gordonii
To verify that S. gordonii GP1300 released IL-1ra into the
culture medium, strains GP1300 and GP1221 were grown
in TSB to early stationary phase. Culture supernatant sam-
ples were precipitated with 5% TCA and subjected to 15%
sodium dodecyl sulfate-polyacrylamide gel elecrophoresis
(SDS-PAGE). After transferring onto nitrocellulose filters
(Protran; Schleicher and Schuell, Dassel, Germany),
immunoblotting was performed using a 1:100,000 dilu-
tion of rabbit polyclonal antibodies raised against human
IL-1ra expressed and purified from E. coli (see below).
Quantitative assessment of IL-1ra in the culture superna-
tant of S. gordonii GP1300 was performed by ELISA using
the IL-1ra Biotrak ELISA kit (Amersham Biosciences, Little
Chalfont, UK) in accordance to the manufacturer's
instructions.
Expression and purification of human IL-1β, IL-1ra, and 
RVFP/IL-1ra in E. coli
Human IL-1β, IL-1ra, and the RVFP/IL-1ra construct were
expressed and purified from E. coli. The cDNAs coding for
the mature human IL-1β (GenBank accession number
NM_000576), human IL-1ra, and RVFP/IL-1ra were
cloned into the pRSET vector (Invitrogen, San Diego, CA),
as previously described [52]. Expression of recombinant
proteins was induced with 1 mM isopropyl β-D-thioga-
lactopyranoside (IPTG; Inalco, Milano, Italy), according
to the manufacturer's instructions. Cells were harvested,
disrupted by sonication, and the soluble fraction was col-
lected by centrifugation. Purification was performed by
chromatography on S-Sepharose Fast Flow (Pharmacia,
Uppsala, Sweden), or Mono S 5/5 column (Pharmacia),
followed by filtration using Centriplus 100 (Amicon, Bev-
erly, MA). Purity was always higher than 95%, as evalu-
ated by SDS-PAGE and densitometric analysis.
Concentration of proteins in 6 M Guanidine-HCl was
determined by calculating the extinction coefficients
using the PC/Gene Software (Oxford Molecular, Cam-
bridge, UK). Purified proteins were tested for biological
activity using the assay of IL-1β-induced D10.G4.1 prolif-
eration [53]. Binding to IL-1 receptors was analysed using
both EL4-6.1 (expressing the IL-1RI receptor) and dexam-
ethasone-treated 1H7 cells (expressing the IL-1RII recep-
tor) [54]. The IL-1β activity was approximately 2.5 × 108
IU (International Units; [55]) per mg of protein, and KD
were 0.12 nM and 0.61 nM for IL-1RI and IL-1RII, respec-
tively. Inhibitory activities of the IL-1ra preparations were
approximately 1.0 × 106 AU/mg, where one AU is the
amount of IL-1ra that inhibits 50% of IL-1β-induced
proliferation in the thymocytes proliferation assay (see
below).
Thymocyte proliferation assay
Normal thymocytes (5 × 105 cells/well) from 4–8 week
old C3H/HeJ mice (The Jackson Laboratory, Bar Harbor,
ME) were incubated in microtitre plates (Cluster96, Cos-
tar, Cambridge, MA) in cell culture medium at 37°C with
5% CO2 for 72 hours. Culture medium was RPMI 1640
medium (Invitrogen, Life Technologies Inc., Carlsbad,
CA), supplemented with 50 µg/ml of gentamycin
(Sigma), 2 mM L-glutamine, 1.25 × 105 M 2-mercaptoeth-
anol, 25 mM HEPES buffer, and 5% heat-inactivated fetal
bovine serum (Hyclone, Sterile Systems, Logan, UT). Cells
were incubated with a suboptimal concentration of phy-
tohemoagglutinin (PHA, 1.5 µg/ml; GlaxoSmithKline,
Brentford, UK) together with an optimal concentration of
recombinant human IL-1β (typically 0.3 ng/ml). Serial
dilutions of either S. gordonii GP1300 culture supernatant
(containing 0.1 mg/litre of RVFP/IL-1ra) or purified E. coli
RVFP/IL-1ra were tested for their capacity to inhibit IL-1β-
induced proliferation, as compared to a standard curve of
human recombinant IL-1ra expressed in E. coli. The latter
reagent was repeatedly titrated for its IL-1β inhibitor activ-
ity in the thymocyte proliferation assay, yielding an aver-
age specific activity of 1.0 × 106  AU/mg. The same
standardised preparation of wild type human recom-
binant IL-1ra was used as a reference standard in each
assay [56]. Supernatant of the control GP1221 strain was
used as a negative control. After 72 hours of incubation,BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/15
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each well received 25 µl of culture medium containing 0.5
µCi  3H-thymidine (Amersham), and plates were incu-
bated for 18 hours. Cells were harvested on glass fiber fil-
ters and incorporated radioactivity was measured with a β-
counter (Betaplate, Wallac, Turku, Finland). IL-1β inhibi-
tory activities of IL-1ra-containing samples were calcu-
lated from inhibition curves, expressed in AU per mg of
protein, and compared to the reference wild type IL-1ra
standard.
Murine vaginal colonisation
Six week-old female BALB/c mice (Charles River Italia,
Monza, Italy) were used. The RVFP/IL-1ra-producing
GP1294 and the GP204 control strains were grown in TSB
to late exponential phase, washed once, and resuspended
in fresh medium. Each animal received a single intravagi-
nal inoculum of 108 CFU in a total volume of 20 µl. Vag-
inal samples were collected once per week for 8 weeks
using absorbent cylindrical wicks (Porvair Filtronics Ltd.,
Shepperton, UK), and plated onto blood agar plates con-
taining streptomycin. Bacterial colonies were tested for
erythromycin resistance and expression of IL-1ra by West-
ern blot using an anti-IL-1ra rabbit serum (1:100,000).
Vaginal samples were also subjected to immunofluores-
cence using an IL-1ra antiserum as described before [57].
All procedures for inoculation, collection and processing
of samples, and colonisation assays were as previously
described [57].
Assessment of IL-1ra in the GI tract of mice
Four weeks-old female IL-2 knock-out C57BL/6 mice (IL-
2-/-), generated by gene targeting as previously described
[58], were obtained by Jackson Laboratories (Bar Harbor,
Maine, USA). Mice were inoculated intragastrically with
the S. gordonii GP1294 strain (producing RVFP/IL-1ra).
Details of bacterial preparation and administration to
mice are below. In order to quantify production of RVFP/
IL-1ra in the GI tract, three mice were sacrificed 3, 11, and
28 days after last bacterial inoculum. The stomach, small
intestine, colon, and caecum were isolated, washed in
cold phosphate-buffered saline pH 7.4 (PBS) and imme-
diately homogenised in 2 ml of cold PBS. Homogenates
were centrifuged (8800 × g,10 minutes, 4°C) and super-
natants were stored at -20°C. Faeces and caecum were col-
lected and treated as described [28]. Human IL-1ra was
determined in GI tract samples by ELISA (R&D Systems,
Minneapolis, MN, USA). Culture supernatants of S. gordo-
nii GP1294 and GP204 were used as positive and negative
controls, respectively. Net OD450 readings are reported, as
qualitative indication of IL-1ra presence in the tissues.
Precise quantitative determination of IL-1ra in organ
homogenates is hampered by the presence of receptors,
natural antibodies, and/or other non-specific inhibitors.
As reference, OD450 readings for standard human recom-
binant IL-1ra are the following: 50 pg/ml, 0.018; 100 pg/
ml, 0.030; 500 pg/ml, 0.236; 1000 pg/ml, 0.575.
Treatment of IL-2-/- mice with recombinant S. gordonii
The S. gordonii strains GP1294 (producing RVFP/IL-1ra)
and GP204 (control) were grown in TSB to the beginning
of stationary phase, washed once with PBS, and resus-
pended in PBS containing 3% skimmed milk to a final
concentration of approximately 5 × 1010 CFU/ml. Two
groups of 6 mice each were inoculated intragastrically
twice per week for 7 consecutive weeks (week 4 to 10)
with 200 µl of the bacterial suspension (approximately
1010 CFU/mouse) of either strain GP1294 or GP204. One
untreated mouse served as a control to follow the course
of disease progression. Mice were weighted twice per week
for 15 weeks.
Statistical analysis
Differences in body weights between IL-2-/- mice receiving
S. gordonii GP1294 and GP204 were analysed by using the
unpaired Student's t test. Statistical significance was set at
P < 0.05.
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